New York State Common Retirement Fund Has $20.85 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Common Retirement Fund cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 112,926 shares of the medical research company’s stock after selling 6,799 shares during the period. New York State Common Retirement Fund owned 0.22% of Charles River Laboratories International worth $20,846,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Venturi Wealth Management LLC boosted its position in shares of Charles River Laboratories International by 170.2% in the fourth quarter. Venturi Wealth Management LLC now owns 4,367 shares of the medical research company’s stock valued at $806,000 after acquiring an additional 2,751 shares during the period. Empower Advisory Group LLC raised its stake in Charles River Laboratories International by 2.5% in the 4th quarter. Empower Advisory Group LLC now owns 275,851 shares of the medical research company’s stock worth $50,922,000 after purchasing an additional 6,747 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at about $272,000. Baillie Gifford & Co. grew its position in shares of Charles River Laboratories International by 10.0% during the 4th quarter. Baillie Gifford & Co. now owns 75,411 shares of the medical research company’s stock worth $13,921,000 after purchasing an additional 6,826 shares in the last quarter. Finally, V Square Quantitative Management LLC increased its holdings in shares of Charles River Laboratories International by 12.6% during the fourth quarter. V Square Quantitative Management LLC now owns 1,084 shares of the medical research company’s stock worth $200,000 after purchasing an additional 121 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. The Goldman Sachs Group reduced their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Barclays dropped their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $195.71.

Insider Activity

In other news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James C. Foster bought 6,075 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE:CRL opened at $163.11 on Friday. The firm has a market cap of $8.34 billion, a P/E ratio of 1,087.39, a P/E/G ratio of 4.54 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00. The business has a fifty day simple moving average of $172.84 and a 200 day simple moving average of $188.09. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period last year, the company earned $2.46 earnings per share. The firm’s revenue was down 1.1% compared to the same quarter last year. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).